Stock Research: ScinoPharm

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

ScinoPharm

TSEC:1789 TW0001789006
27
  • Value
    76
  • Growth
    14
  • Safety
    Safety
    18
  • Combined
    16
  • Sentiment
    57
  • 360° View
    360° View
    27
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ScinoPharm Taiwan Ltd. researches, develops, manufactures, and sells active pharmaceutical ingredients. The company operates in the pharmaceutical industry. It serves markets in the Americas, Europe, Australia, and Asia. In the last fiscal year, the company had a market cap of $445 million, profits of $40 million, and revenue of $104 million. The number of employees is not available.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock ScinoPharm are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for ScinoPharm. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 76 or better than 76% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 18, meaning that the share price of ScinoPharm is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 14. ...read more

more
Index
FTSE Taiwan
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
18 18 24 41
Growth
14 37 9 81
Safety
Safety
76 69 78 67
Sentiment
57 42 22 1
360° View
360° View
27 33 14 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
18 12 20 24
Opinions Change
50 50 1 50
Pro Holdings
n/a 40 20 41
Market Pulse
91 87 100 1
Sentiment
57 42 22 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
18 18 24 41
Growth
14 37 9 81
Safety Safety
76 69 78 67
Combined
16 30 20 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
10 12 7 36
Price vs. Earnings (P/E)
19 16 13 26
Price vs. Book (P/B)
47 35 41 65
Dividend Yield
48 36 49 53
Value
18 18 24 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
40 66 26 96
Profit Growth
25 20 10 84
Capital Growth
48 28 26 8
Stock Returns
22 48 51 61
Growth
14 37 9 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
73 67 71 68
Refinancing
60 49 65 67
Liquidity
67 55 63 41
Safety Safety
76 69 78 67

Similar Stocks

Discover high‑ranked alternatives to ScinoPharm and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Hon Hai Precision Industry

TSEC:2317
Country: Taiwan
Industry: Electr. Manufacturing Services
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.